Two recent decisions are quietly redrawing the boundaries of what drug and biologic patents can cover. The Supreme Court’s 2023 decision in Amgen Inc. v. Sanofi tightened the enablement screws on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results